COVID-19 vaccines and booster shots are the best preventive measure available against severe disease, hospitalization and death due to COVID-19. However, some blood cancer patients will not get optimal protection from vaccines. Monoclonal antibodies can provide another layer of protection for blood cancer patients and others who are at high-risk of serious illness if they become infected with COVID-19. However, monoclonal antibodies treatments are currently in short supply.

(This table is for informational purposes only. Treatments require a prescription and should be guided by a patient’s healthcare team.)

### Evusheld (tixagevimab and cilgavimab)

<table>
<thead>
<tr>
<th>Authorized for</th>
<th>Prevention of infection before known exposure to COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>For use in adults, and children 12 and older who weigh at least 88 pounds</td>
<td>Who are not currently infected with COVID-19 and have not had known recent exposure to an infected person and • Are moderately to severely immunocompromised due to a medical condition (such as blood cancer patients and some survivors) or immune-suppressing treatment (e.g., BTK inhibitors, CD20 antibodies, CD-19 CAR T-therapy) and may not mount an adequate immune response to COVID-19 vaccination or • Cannot be vaccinated with any COVID-19 vaccine according to the approved schedule or has had a severe allergic reaction to any vaccine component</td>
</tr>
<tr>
<td>Activity against Omicron</td>
<td>In the laboratory, Evusheld is active against the Omicron variant, but its potency is reduced compared to earlier COVID-19 strains. Activity is retained against the Delta variant. As with vaccines, breakthrough infection is possible after antibody treatment</td>
</tr>
<tr>
<td>Dosing/Timing</td>
<td>As of June 29, 2022, Evusheld is authorized for repeated dosing every six months for patients who need ongoing protection. Given as two consecutive injections into the muscle, one for tixagevimab and one for cilgavimab Evusheld should be deferred for at least two weeks after COVID-19 vaccination Vaccination does not need to be deferred for any period after Evusheld administration</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Manufacturer</td>
<td><a href="#">Click here</a> to read the manufacturer’s Fact Sheet for Patients, Parents and Caregivers.</td>
</tr>
</tbody>
</table>
**Bebtelovimab**

**Authorized for** Treatment of mild-to-moderate COVID-19

**For use in adults, and children 12 and older who weigh at least 88 pounds**

- Who have mild-to-moderate COVID-19 symptoms and have tested positive for the infection, **and**
  - Are not hospitalized or requiring supplemental oxygen, **and**
  - Are at increased risk of progressing to severe COVID-19 (such as blood cancer patients and some survivors)

**Activity against Omicron**

Expected to protect against serious outcomes of infection, including with the omicron variant and the recently identified omicron subvariant.

**Dosing/Timing**

- There is no waiting period between bebtelovimab and COVID-19 vaccination, or between COVID-19 vaccination and bebtelovimab.
- Given as a single IV injection over at least 30 seconds.
- Should be given as soon as possible after positive results of a COVID-19 test and within 7 days of symptom onset.

**Manufacturer**

Eli Lilly

Click here to read the manufacturer’s Fact Sheet for Patients, Parents and Caregivers.

---

**Note:** Treatment with bebtelovimab is recommended as an alternative only when the antivirals Paxlovid and remdesivir are not available, feasible to use, or clinically appropriate.

---

**Xevudy (sotrovimab)**

As of April 5, 2022, the FDA advised that “the authorized dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant. Due to these data, sotrovimab is not authorized in any U.S. state or territory at this time.”

Click here to read more.

---

**Regen-COV (casirivimab and imdevimab)**

As of January 24, 2022, the FDA advised that “this treatment is not authorized for use in any U.S. states, territories or jurisdictions because it is highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States.”

Click here to read more.

---

**Bamlanivimab and etesevimab**

As of January 24, 2022, the FDA advised that “this treatment is not authorized for use in any U.S. states, territories or jurisdictions because it is highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States.”

Click here to read more.

---


As of July 15, 2022

The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Find out more at www.LLS.org.